The quarter cleared the market's bar. Published expectations were roughly $1.39 for adjusted EPS and $9.64 billion of revenue; Medtronic delivered $1.45 and $9.756 billion, respectively.
| Metric | Q1 FY27 | Q1 FY26 | Published expectation |
|---|---|---|---|
| Revenue | $9.756B (Financial Highlights) | $8.578B (Income Statement) | ~$9.64B |
| Non-GAAP diluted EPS | $1.45 (GAAP to Non-GAAP Reconciliation) | $1.26 (GAAP to Non-GAAP Reconciliation) | ~$1.39 |
| Non-GAAP operating margin | 23.7% (GAAP to Non-GAAP Reconciliation) | 23.6% (GAAP to Non-GAAP Reconciliation) | — |
| Free cash flow | $1.290B (Cash Flow statement) | $584M (Cash Flow statement) | — |
| FY27 organic revenue growth guide | 7.25%-7.75% (Guidance) | Prior: 6.75%-7.25% | — |
| FY27 non-GAAP EPS guide | $5.94-$6.00 (Guidance) | Prior: $5.90-$6.00 | — |
The beat was broad, but not entirely clean. Organic revenue rose 13.7%, with Cardiovascular up 18.9%, Neuroscience up 9.3%, and Medical Surgical up 10.2% (Worldwide Revenue). The company also said, "The company today raised its FY27 organic revenue growth and EPS guidance." 〔0〕
The calendar supplied a meaningful part of the headline acceleration. FY27 includes 53 weeks, and Medtronic estimates the extra week added approximately $570 million to Q1 organic growth (Worldwide Revenue). That is roughly half of the year-over-year revenue increase, so the underlying operating gain is closer to the high-single-digit range than the reported 13.7% organic figure.
The forward revision is positive but modest. Revenue-growth guidance moved up by 50 basis points at both ends, while the EPS range increased only at the low end and its midpoint moved from $5.95 to $5.97. The limited EPS revision, alongside just 10 basis points of non-GAAP operating-margin expansion, suggests the upside was more about execution and volume than a major profitability reset.
Net: a real beat, with a small upgrade rather than a wholesale change in the story. Strong Cardiovascular growth, higher cash generation, and raised guidance outweigh the calendar distortion; however, the extra week and restrained EPS upgrade keep this from reading as a large expectation reset.
Read the original 8-K on SEC EDGAR ↗